Big Vaccine Update Gives JNJ A Leg Up


Johnson & Johnson JNJ vaccine

Johnson & Johnson (NYSE: JNJ) is in the spotlight this morning after the U.S. Food and Drug Administration (FDA) deemed the drugmaker's one-shot COVID-19 vaccine safe and effective. A panel of independent experts to the FDA are slated to meet at the end of the week to make a final approval decision. In response, the security is up 1.4% at $162.65 in early trading. 

JNJ has been cooling since hitting its record high of $173.65 in late January. The equity did attempt a second rally back to these levels earlier this month, but this was met with resistance at the $168 level. The 50-day moving average looks to be coming in as a leg of support, however, and JNJ has managed to remain just north of its year-to-date breakeven, sporting a roughly 2% lead. 

Analysts have remained optimistic. All but three of the 13 in coverage consider Johnson & Johnson stock to be a "buy" or better. Meanwhile, the 12-month consensus price target of $185.44 is a 14.3% premium to current levels. 

Options traders have echoed this sentiment. This is per JNJ's 50-day call/put volume ratio of International Securities Exchange (ISE), Cboe Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX), which stands higher than 89% of readings from the past year. This means this heavy penchant for bullish bets is unusual.

Similarly, the stock's Schaeffer's put/call open interest ratio (SOIR) of 0.44 stands higher than only 10% of readings from the past 12 months. In simpler terms, this suggests short-term traders have rarely been more call-biased on JNJ.

Disclaimer: Schaeffer's Investment Research ("SIR" or "we" or "us") is not registered as an investment adviser. SIR relies upon the "publishers' ...

How did you like this article? Let us know so we can better customize your reading experience.


Leave a comment to automatically be entered into our contest to win a free Echo Show.